| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5362755 | HIKMA | Method for treating asthma using optically pure (R)-albuterol |
Mar, 2013
(11 years ago) | |
| US5547994 | HIKMA | Method for treating asthma using optically pure R(-) albuterol |
Aug, 2013
(10 years ago) | |
| US6451289 | HIKMA | Albuterol formulations |
Mar, 2021
(3 years ago) | |
Xopenex is owned by Hikma.
Xopenex contains Levalbuterol Hydrochloride.
Xopenex has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Xopenex are:
- US5362755
- US5547994
- US6451289
Xopenex was authorised for market use on 30 January, 2002.
Xopenex is available in solution;inhalation dosage forms.
Xopenex can be used as treatment or prevention of bronchospasm.
The generics of Xopenex are possible to be released after 21 March, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-151) | Jan 22, 2018 |
Drugs and Companies using LEVALBUTEROL HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2002
Treatment: Treatment or prevention of bronchospasm
Dosage: SOLUTION;INHALATION
How can I launch a generic of XOPENEX before it's drug patent expiration?
More Information on Dosage
XOPENEX family patents
